- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Cyclerion Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 04.12.23 | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.12.23 | Cyclerion Therapeutics falls as CEO steps down | 1 | Reuters | ||
| 04.12.23 | Cyclerion Therapeutics appoints Graul as President | 2 | Seeking Alpha | ||
| 01.12.23 | Cyclerion Therapeutics, Inc.: Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator | 1 | GlobeNewswire (USA) | ||
| 24.11.23 | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.11.23 | Cyclerion Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.06.23 | Cyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement | 328 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. ("Cyclerion" or the "Company") (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq... ► Artikel lesen | |
| 15.05.23 | Cyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock Split | 298 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the "Company", "Cyclerion Therapeutics", "Cyclerion") (Nasdaq: CYCN) announced today that it will effect a reverse stock... ► Artikel lesen | |
| 12.05.23 | Cyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial Results | 306 | GlobeNewswire (Europe) | Definitive agreement reached with new company ("NewCo") established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,160 | -4,98 % | Allianz, Evotec, Nel ASA, Nordex, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QIAGEN | 37,940 | -1,65 % | Biotech Report: Evotec und Qiagen behauptet, US-Sektor verliert | (shareribs.com) Frankfurt / New York 18.04.2024 - Biotech-Aktien zeigen sich im freundlichen Handel uneinheitlich. Evotec und Qiagen notieren etwas fester. An der Wall Street geben Gilead Sciences und... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,690 | -3,15 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| IMMUNOVANT | 27,750 | -3,65 % | Should You Hold Immunovant (IMVT)? | ||
| KYMERA THERAPEUTICS | 33,350 | -5,23 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| RECURSION PHARMACEUTICALS | 7,840 | -1,26 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,170 | -3,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,200 | +1,89 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| ARCUTIS BIOTHERAPEUTICS | 8,590 | -1,83 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,695 | -5,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 13,210 | -13,03 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| KEROS THERAPEUTICS | 54,19 | -3,65 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,600 | -5,01 % | Expert Ratings For Beam Therapeutics | ||
| SANA BIOTECHNOLOGY | 8,500 | -0,93 % | Sana Biotechnology, Inc. - 8-K, Current Report | ||
| ARVINAS | 31,600 | -2,89 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |
Das Unternehmen CYCLERION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,140 Euro und damit +12,54 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
